Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 203 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Understanding Serving Sizes January 15, 2021 PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows May 11, 2020 EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... January 20, 2023 Load more HOT NEWS Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated... R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification... Selumetinib Continues to Show Promise in Children with NF1 Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy...
